Highlights
- 1Clinical cancer research : an official journal of the American Association for Cancer Research · 2023
- 2Journal of the National Cancer Institute · 2024
- 3NPJ precision oncology · 2023
Publications
290 publications
Funding
24 grantsView NIH portfolio on RePORTER ↗
Active
4 grants- MPI"DNMT and TET1 reprogramming as a targetable mechanism of resistance in advanced prostate cancer"NCI · 2023–2028 · via NIH RePORTERR01CA274963-04
- Co-IOptimization of Prostate-Specific Membrane Antigen-Targeted RadiationProstate Cancer Foundation · 2017–202717CHAL11
- PIMolecular mechanisms underlying lineage plasticity in prostate cancerNCI · 2020–2027 · via NIH RePORTERR37CA241486-07
Completed grants (20)
- Co-ITargeting Genomic, Metabolic and Immunological Vulnerabilities of Colorectal CancerAmerican Association for Cancer Research · 2017–2024 · via Sloan-Kettering Institute for Cancer ResearchSU2C-AACR-DT22-17
- Co-IWeill Cornell Medicine (WCM) SPORE in Prostate CancerNational Cancer Institute · 2017–2023P50CA211024-05
- KPPersonalized in vitro models to advance precision medicineNational Cancer Institute · 2019–2023 · via Leidos Biomedical ResearchHHSN26100008
- Co-IProstate Cancer Clinical Consortium Clinical Research Site: Targeted TherapiesU.S. Department of Defense · 2018–2022W81XWH-18-2-0032
- Co-IClinical and Translational Science Center - UL1National Center for Advancing Translational Sciences · 2017–2022UL1TR002384-01
- Co-ICENTER ON THE PHYSICS OF CANCER METABOLISM -Microfabrication Core 10802National Cancer Institute · 2016–2021 · via Cornell University - IthacaU54CA210184-05
- PITemporal Evolution of N-Myc Signaling and Early Targeting of the Neuroendocrine Phenotype in Prostate CancerU.S. Department of Defense · 2017–2020W81XWH-17-1-0653
- Co-IMechanistic Insights Underlying ERG-Induced Taxane Resistance in Castration-Resistant Prostate CancerNational Cancer Institute · 2014–2020R01CA179100-05
- Co-IIdentification of Antibody Therapeutics for Treatment of Neuroendocrine Prostate CancerJanssen Research & Development, LLC · 2016–2019ContractJanssen RAA
- KPPrecision Medicine SequencingProstate Cancer Foundation · 2012–2019PCF 170814-EWOF
- PIImpact of Therapy on Modulation of Neuroendocrine-Associated Gene Expression in Patients With High Risk, Localized Prostate Cancer Treated With Neoadjuvant Docetaxel and Androgen Deprivation TherapyAlliance for Clinical Trials in Oncology · 2015–2018ACT 15050798-02
- PITargeting BRN2 in Neuroendocrine Prostate CancerProstate Cancer Foundation · 2017–201817CHAL13
- PIEarly Detection of Neuroendocrine Prostate Cancer Transformation Using Circulatin Genomic SignaturesProstate Cancer Foundation · 2014–2018PCF 15111792-02
- Co-IProstate Cancer Clinical Consortium Clinical Research Site: Targeted TherapiesU.S. Department of Defense · 2014–2018W81XWH-14-2-0159 Yr
- PIA Changing Landscape of Advanced Prostate Cancer: Understanding Mechanisms of Resistance to Potent Hormonal TherapiesU.S. Department of Defense · 2013–2018FellowshipW81XWH-13-1-0275
- PIDevelopment and Qualification of the PCF SELECT (Specific Evaluation in Liquid Biopsies of Established Prostate Cancer Targets) Plasma DNA AssayProstate Cancer Foundation · 2016–201816CHAL01
- Sub-PIMolecular Mechanics of Response to Combination Therapy in Early Lethal PCANational Cancer Institute · 2016–2018 · via The Brigham & Women's Hospital INCU10CA180821-04
- KPMolecular Signatures of Lethal and Indolent Prostate CancerNational Cancer Institute · 2012–2017R01CA116337-09
- KPTowards Understanding Prostate Cancer HeterogeneityNational Cancer Institute · 2013–2017R01CA125612-09
Honors & distinctions
1 honor
- Damon Runyon Fellowship / Grant · Damon Runyon Cancer Research Foundation · 2013